Hemab Therapeutics Holdings, Inc. Common Stock

NASDAQ:COAG

Biotechnology

Healthcare
$39.15 +8.79%

+$2.32 today

Market cap
$1.83B
Beta
0.00
52W Low $23.00High $36.61

Volume 0.30M

Average 0.34M

COAG Short-term Investments

Marketable securities and deposits the company expects to convert to cash within a year.

Hemab Therapeutics Holdings, Inc. Common StockNASDAQ: COAG

Short-term Investments · Q2 FY2026 · quarter ended Jun 2026

Short-term investments of $220.09M in Q2 FY2026

Q2 FY2026 short-term investments was $220.09M.

Context

  • Short-term investments amounted to 47.1% of total assets at the end of Q2 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$220.09M+93.6% QoQ
Last fiscal yearDec 2025
$97.51M— YoY
Short-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Investments history

USD · from the balance sheet

Latest · FY2025
97.51M USD
Year-over-year change
—

Short-term Investments vs competitors

How COAG compares with its peers on the latest reported figures

  • COAG's Jun 2026 short-term investments of $220.09M is the 3rd highest of the 5 companies compared; the peer median is $226.03M.
  • Short-term investments amounts to 47.1% of total assets for COAG, versus a peer median of 33.7%.
COAG Competitors Peer median
Short-term Investments for COAG and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IRONDisc Medicine, Inc.Sep 2026$592.83M +24.7%—84.8%
QUREuniQure N.V.Mar 2026$446.56M +132.8%+63.2%57.3%
COAGHemab Therapeutics Holdings, Inc. Common StockJun 2026$220.09M ——47.1%
RLYBRallybio CorporationMar 2026$5.5M -86.2%-40.7%10.1%
DMRADamora Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding COAG) $226.03M+24.7%+11.2%33.7%

Competitors are the stored peer set for COAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Hemab Therapeutics Holdings, Inc. Common Stock

NASDAQ:COAG

Intrinsic Alpha fair value

Locked

Current Price

$39.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.